Patient Assistance

CASODEX 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone analog (LHRH-A) for the treatment of Stage D2 metastatic carcinoma of the prostate.

CASODEX 150 mg daily is not approved for use alone or with other treatments (see Clinical Studies section 14.2 in the full Prescribing Information ).

• Serum transaminase levels should be measured prior to starting treatment with CASODEX, at regular intervals for the first four months of treatment, and periodically thereafter.

• Development of diabetes has been reported in men receiving LHRH-As. Consider monitoring blood glucose in patients receiving CASODEX with an LHRH-A.

• The most commonly reported adverse events regardless of causality for CASODEX plus an LHRH-A were hot flashes (53%), pain (35%), back pain (25%), asthenia (22%), constipation (22%), pelvic pain (21%), infection (18%), nausea (15%), dyspnea (13%), peripheral edema (13%), diarrhea (12%), hematuria (12%), and nocturia (12%).

Please click here for full Prescribing Information for CASODEX.

ZOLADEX 3.6 mg depot and 10.8 mg depot are indicated in the palliative treatment of advanced carcinoma of the prostate.

ZOLADEX 3.6 mg depot and 10.8 mg depot are also indicated for use in combination with flutamide for the management of locally advanced Stage T2b-T4            (Stage B2-C) carcinoma of the prostate. Treatment with the combination should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy.

• ZOLADEX, like other luteinizing hormone-releasing hormone analogs (LHRH-As), may cause a transient rise in testosterone. When used alone, there may be a temporary worsening of prostate cancer symptoms at the start of therapy.

• Development of diabetes has been reported in men receiving LHRH-As like ZOLADEX. Consider monitoring blood glucose in patients receiving ZOLADEX.

• The most common adverse events (incidence > 5%) in advanced carcinoma of the prostate clinical trials were: for ZOLADEX 3.6 mg depot—hot flashes (62%), sexual dysfunction (21%), decreased erections (18%), lower urinary tract symptoms (13%), lethargy (8%), pain (worsened in the first 30 days) (8%), edema (7%), upper respiratory infection (7%), rash (6%), and sweating (6%); for ZOLADEX 10.8 mg depot—hot flashes (64%), pain (general) (14%), gynecomastia (8%), pelvic pain (6%), and bone pain (6%).

• In the locally advanced carcinoma of the prostate clinical trial, additional adverse event data were collected for the combination therapy with radiation group during both the hormonal treatment and hormonal treatment plus radiation phases of this study. Adverse experiences (incidence > 5%) in both phases of this study were hot flashes (46%), diarrhea (40%), nausea (9%), and skin rash (8%).

Please click here for full Prescribing Information for ZOLADEX 3.6 mg 1-month Depot.
Please click here for full Prescribing Information for ZOLADEX 10.8 mg 3-month Depot.